Kings Path Partners
EW icon

Kings Path Partners’s Edwards Lifesciences EW Stock Holding History

Kings Path Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$691 Hold
8
– – ﹤0.01% 353
2026
Q2 		$724 Buy
+8
New +$670 ﹤0.01% 335

Other funds holding EW

Ninety One (UK)
Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $33.8B AUM 31.08% 1-Year Est. Return
Birch Hill Investment Advisors
Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Seilern Investment Management
Seilern Investment Management London, United Kingdom $771M AUM 2.59% 1-Year Est. Return
Ninety One North America
Ninety One North America New York $2.13B AUM 8.8% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
ABN AMRO Investment Solutions
ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Kings Path Partners's EW Position: Q3 2026 in Review

Kings Path Partners held its Edwards Lifesciences (EW) position steady in Q3 2026 at 8 shares worth $691. The position accounts for ﹤0.01% of the portfolio, ranked #353.

Kings Path Partners first reported a position in EW in Q2 2026 and has held it in 2 quarters since. The position peaked at $724 in Q2 2026. 297 funds tracked by Wall St. Rank hold EW as of Q3 2026.

  • Kings Path Partners held 8 shares of Edwards Lifesciences worth $691 as of Q3 2026.
  • Kings Path Partners left its Edwards Lifesciences share count unchanged in Q3 2026.
  • Edwards Lifesciences made up ﹤0.01% of Kings Path Partners's portfolio in Q3 2026, its #353 holding.
  • Kings Path Partners first reported a position in Edwards Lifesciences in Q2 2026 and has held it in 2 quarters since.
  • Kings Path Partners's Edwards Lifesciences position peaked at $724 in Q2 2026.
  • 297 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Kings Path Partners's 13F filing for Q3 2026, filed 21 Oct 2026.